Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

• Status: Completed
• Trial end date: 2008-09-01

Summary

The purpose of this study is to assess whether a calcineurin inhibitor (CNI)-free regimen with enteric-coated mycophenolate sodium (EC-MPS) and everolimus is as safe and well-tolerated as the standard regimen containing enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine microemulsion, but results in better renal function.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Cyclosporine; Cyclosporins; Everolimus; Immunosuppressive Agents; Mycophenolate mofetil; Mycophenolic Acid; Prednisolone; Sirolimus